Key result
ManNAc restores polysialylation and intracellular sialic acid to wild-type levels in GNE-deficient cells.
Why the study?
Impaired sialic acid synthesis is implicated in GNE myopathy, prompting investigation into whether N-acetylmannosamine can restore sialic acid content in GNE-deficient cells.
Does N-acetylmannosamine (ManNAc) supplementation restore sialic acid levels in GNE-deficient HEK-293 cells?
Does N-acetylmannosamine (ManNAc) supplementation restore sialic acid levels in GNE-deficient HEK-293 cells?
Absolute Event Rate: 0.8979% vs 1%
p-value: p=0.2099
ManNAc supplementation can restore polysialylation and sialic acid levels in a GNE-knockout HEK-293 cell model, supporting its potential as a therapeutic precursor for GNE myopathy.
No takes yet. Share an insight, caveat, or question.
ManNAc may support precursor therapy in GNE myopathy; leaves open clinical translation from cell models.
Peters et al. (2023) studied GNE myopathy (in vitro model). N-acetylmannosamine (ManNAc) vs. Wild type HEK-293 cells / untreated GNE-knockout cells was evaluated on Relative normalized polysialylation signal (p=0.2099). Supplementation of GNE-deficient HEK-293 cells with 2 mM ManNAc restored polysialylation and free intracellular sialic acid levels to wild type levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: